Table 4.
Summary of adverse events (AEs)
| N (%) | Experimental group (n = 57) | Control group (n = 60) | Risk ratio (95% CI) | p Value |
|---|---|---|---|---|
| Total events | 8 (14.04%) | 8 (13.33%) | 1.053 (0.424, 2.616) | 0.628 |
| Readmission for HF | 6 (10.52%) | 5 (8.33%) | – | – |
| Angina pectoris | 1 (1.75%) | 0 | – | – |
| Heart transplantation | 0 | 1 (1.67%) | – | – |
| Ventricular arrhythmia | 1 (1.75%) | 2 (3.34%) | – | – |
| AEs in patients > 65 years old | 1 (1.75%) | 3 (5.00%) | – | 0.326 |
| Atrial fibrillation at 24-week visita | 5 (8.77%) | 6 (10.00%) | 0.877 (0.283, 2.716) | 0.820 |
| Death | 5 (8.77%) | 7 (11.67%) | 0.752 (0.253, 2.234) | 0.510 |
| Cardiac death | 4 (7.02%) | 7 (11.67%) | – | – |
| Non-cardiac death | 1 (1.75%) | 0 | – | – |
a
Atrial fibrillation was detected by 24-h Holter test.